<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; ZymoGenetics Inc</title>
	<atom:link href="http://www.stockbloghub.com/tag/zymogenetics-inc/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Thu, 24 May 2012 23:16:35 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(ACHN) Achillion Pharmaceuticals&#8217; Pipeline Makes Progress</title>
		<link>http://www.stockbloghub.com/2010/10/03/achn-achillion-pharmaceuticals-pipeline-makes-progress/53720</link>
		<comments>http://www.stockbloghub.com/2010/10/03/achn-achillion-pharmaceuticals-pipeline-makes-progress/53720#comments</comments>
		<pubDate>Mon, 04 Oct 2010 05:11:51 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Achillion Pharmaceuticals Inc]]></category>
		<category><![CDATA[ACHN]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Valeant Pharmaceuticals International]]></category>
		<category><![CDATA[VRX]]></category>
		<category><![CDATA[ZGEN]]></category>
		<category><![CDATA[ZymoGenetics Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=53720</guid>
		<description><![CDATA[Recently, Achillion Pharmaceuticals, Inc. (ACHN) announced that it has started dosing patients in a randomized, double-blind mid-stage study (n~120) that will evaluate pipeline candidate ACH-1625. The candidate is being developed to treat patients infected with hepatitis C virus (HCV). The placebo-controlled phase IIa study, to be conducted in the United States and Europe, will evaluate the safety, tolerability and antiviral activity of the HCV candidate as a combination therapy. Specifically, ACH-1625 (an oral candidate) will be evaluated in conjunction with pegylated interferon alfa-2a and ribavirin after 4 and 12 weeks of dosing in patients infected with chronic HCV genotype 1. While results from the 4 week study are expected in the first quarter of 2011, the 12 week study results are anticipated by the end of 2011. ACH-1625, a HCV ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/10/03/achn-achillion-pharmaceuticals-pipeline-makes-progress/53720/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BMY) Company News for September 8, 2010 &#8211; Corporate Summary</title>
		<link>http://www.stockbloghub.com/2010/09/08/bmy-company-news-for-september-8-2010-corporate-summary/50773</link>
		<comments>http://www.stockbloghub.com/2010/09/08/bmy-company-news-for-september-8-2010-corporate-summary/50773#comments</comments>
		<pubDate>Wed, 08 Sep 2010 18:05:27 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[China Mobile Limited]]></category>
		<category><![CDATA[CHL]]></category>
		<category><![CDATA[Goldman Sachs Group]]></category>
		<category><![CDATA[GS]]></category>
		<category><![CDATA[INTC]]></category>
		<category><![CDATA[Intel Corporation]]></category>
		<category><![CDATA[NAV]]></category>
		<category><![CDATA[Navistar International Corporation]]></category>
		<category><![CDATA[Phillips-Van Heusen Corporation]]></category>
		<category><![CDATA[PVH]]></category>
		<category><![CDATA[RIG]]></category>
		<category><![CDATA[SFD]]></category>
		<category><![CDATA[Smithfield Foods Inc.]]></category>
		<category><![CDATA[SPLS]]></category>
		<category><![CDATA[Staples]]></category>
		<category><![CDATA[Transocean Limited]]></category>
		<category><![CDATA[UBS]]></category>
		<category><![CDATA[UBS AG]]></category>
		<category><![CDATA[VOD]]></category>
		<category><![CDATA[Vodafone Group plc]]></category>
		<category><![CDATA[Wells Fargo & Company]]></category>
		<category><![CDATA[WFC]]></category>
		<category><![CDATA[ZGEN]]></category>
		<category><![CDATA[ZymoGenetics Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=50773</guid>
		<description><![CDATA[• Bristol-Meyers (NYSE:BMY) said it agreed to acquire ZymoGenetics (NASDAQ:ZGEN) for $9.75 per share, in a deal valued at 885 million • A Bloomberg report said Vodafone (NASDAQ:VOD) will sell its stake in China Mobile (NYSE:CHL) for $6.6 billion • Smithfield Foods (NYSE:SFD) posted inline fiscal first quarter earnings of 46 cents a share on a 6.9% revenue increase to $2.90 billion, below estimates of $3.06 billion • Phillips-Van Heusen (NYSE:PVH) reported better-than-expected second quarter earnings of 72 cents a share, up from estimates of 54 cents on inline revenues of $1.1 billion, up 108% YoY. The firm also offered upside fiscal 2011 earnings and revenue guidance, with earnings of $3.70-$3.80 and revenues of $4.44-$4.47 billion anticipated • Navistar (NYSE:NAV) reported estimate-topping second quarter earnings of $1.83 a share, up from estimates of $1.47, on ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/09/08/bmy-company-news-for-september-8-2010-corporate-summary/50773/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(KG) King Pharmaceuticals&#8217; Quarterly Report Disappoints &#8211; Revenues Slide</title>
		<link>http://www.stockbloghub.com/2010/05/05/kg-king-pharmaceuticals-quarterly-report-disappoints-revenues-slide/36255</link>
		<comments>http://www.stockbloghub.com/2010/05/05/kg-king-pharmaceuticals-quarterly-report-disappoints-revenues-slide/36255#comments</comments>
		<pubDate>Wed, 05 May 2010 21:06:41 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[KG]]></category>
		<category><![CDATA[King Pharmaceuticals Inc.]]></category>
		<category><![CDATA[ZGEN]]></category>
		<category><![CDATA[ZymoGenetics Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=36255</guid>
		<description><![CDATA[King Pharmaceuticals Inc (KG) reported first-quarter earnings of 14 cents per share, well below the Zacks Consensus Estimate of 24 cents and the year-ago earnings of 26 cents. Revenues fell 11.2% from the year-ago quarter to $380.9 million. The Quarter in Detail King&#8217;s branded Pharmaceuticals segment declined 12.9% with revenues coming in at $242 million. Revenues of all key products excluding Flector Patch declined from the year-ago period. Thrombin-JMI sales declined to $37 million, down 21.3%. We expect Thrombin-JMI sales to continue declining due to the tough competition in the form of ZymoGenetics&#8216; (ZGEN) Recothrom and Omrix Biopharmaceuticals&#8216; (OMRI) Evithrom. Meanwhile, Skelaxin, which posted sales of $91 million (down 9.9%), is facing stiff competition from Cephalon&#8216;s (CEPH) Amrix. Amrix&#8217;s once-daily dosing regime and low rate of somnolence should provide it ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/05/05/kg-king-pharmaceuticals-quarterly-report-disappoints-revenues-slide/36255/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(KG) King Pharmaceuticals Misses Earnings Expectations by a Penny</title>
		<link>http://www.stockbloghub.com/2010/02/28/kg-king-pharmaceuticals-misses-earnings-expectations-by-a-penny/29115</link>
		<comments>http://www.stockbloghub.com/2010/02/28/kg-king-pharmaceuticals-misses-earnings-expectations-by-a-penny/29115#comments</comments>
		<pubDate>Mon, 01 Mar 2010 04:15:34 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[KG]]></category>
		<category><![CDATA[King Pharmaceuticals Inc.]]></category>
		<category><![CDATA[Pain Therapeutics Inc.]]></category>
		<category><![CDATA[PTIE]]></category>
		<category><![CDATA[ZGEN]]></category>
		<category><![CDATA[ZymoGenetics Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=29115</guid>
		<description><![CDATA[King Pharmaceuticals, Inc. (KG) reported fourth-quarter earnings of 23 cents per share, a penny below the Zacks Consensus Estimate. Despite fourth quarter revenues increasing 26.1% from the year-ago period, earnings declined 20.6% from the year-ago quarter, mainly due to higher operating expenses. Full-year earnings, which came in a couple of cents above the Zacks Consensus Estimate at $1.10, declined 28.6% from the year-ago period. Meanwhile, full-year revenues increased 14% to $1.78 billion. Fourth-Quarter Performance Fourth-quarter revenues came in at $439.1 million. King&#8217;s branded pharmaceuticals segment remained flat with revenues coming in at $277 million. While Avinza revenues remained flat, both Skelaxin and Thrombin-JMI sales continued to decline on a year-over-year basis. Thrombin-JMI sales came in at $44 million, down 22.8%. We expect Thrombin-JMI sales to continue declining due to the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/02/28/kg-king-pharmaceuticals-misses-earnings-expectations-by-a-penny/29115/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ZGEN) ZymoGenetics Beats Earnings Expectations by a Penny</title>
		<link>http://www.stockbloghub.com/2010/02/15/zgen-zymogenetics-beats-earnings-expectations-by-a-penny/28014</link>
		<comments>http://www.stockbloghub.com/2010/02/15/zgen-zymogenetics-beats-earnings-expectations-by-a-penny/28014#comments</comments>
		<pubDate>Mon, 15 Feb 2010 23:11:23 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[ZGEN]]></category>
		<category><![CDATA[ZymoGenetics Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=28014</guid>
		<description><![CDATA[ZymoGenetics, Inc. (ZGEN) reported fourth quarter earnings of 19 cents per share, which was above the Zacks Consensus Estimate by a penny. The company had suffered a loss of 13 cents in the year-ago quarter. For full year 2009, the company suffered a loss of 62 cents per share, which compares favorably to the loss of $1.69 suffered in fiscal 2008. Revenues for the quarter came in at $62.1 million as against $36 million in the year-ago quarter, up 72.5%. Total revenue for 2009 came in at $136.9 million as against approximately $73.9 million in 2008. Net sales of Recothrom came in at $29.6 million for the full year 2009 and $10.6 million for the fourth quarter of 2009. Recothrom net sales were $4.6 million and $8.8 million in the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/02/15/zgen-zymogenetics-beats-earnings-expectations-by-a-penny/28014/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ZGEN) ZymoGenetics Announced Plans to Offer 12 Million Common Shares</title>
		<link>http://www.stockbloghub.com/2010/01/08/zgen-zymogenetics-announced-plans-to-offer-12-million-common-shares/24449</link>
		<comments>http://www.stockbloghub.com/2010/01/08/zgen-zymogenetics-announced-plans-to-offer-12-million-common-shares/24449#comments</comments>
		<pubDate>Fri, 08 Jan 2010 21:18:37 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ZGEN]]></category>
		<category><![CDATA[ZymoGenetics Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=24449</guid>
		<description><![CDATA[ZymoGenetics Inc. (ZGEN) recently announced that it will sell 12 million shares of its common stock in a public offering. The underwriters will have a 30-day option to purchase up to a further 1.8 million shares of common stock to cover any over-allotments. The sole manager for the offering is Leerink Swann. The public offering amounts to approximately 17% of ZymoGenetics’ total outstanding shares of about 69.3 million as of Oct 30, 2009. The offer, which has not yet been priced by ZymoGenetics, is expected to raise more than $80 million. ZymoGenetics intends to utilize part of the net proceeds from the public offering to support sales of its sole marketed product, Recothrom. The balance amount will be used for general corporate purposes and research and development of other pipeline ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/08/zgen-zymogenetics-announced-plans-to-offer-12-million-common-shares/24449/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ZGEN) ZymoGenetics Amends Recothrom Deal</title>
		<link>http://www.stockbloghub.com/2009/12/22/zgen-zymogenetics-amends-recothrom-deal/23449</link>
		<comments>http://www.stockbloghub.com/2009/12/22/zgen-zymogenetics-amends-recothrom-deal/23449#comments</comments>
		<pubDate>Wed, 23 Dec 2009 00:55:53 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ZGEN]]></category>
		<category><![CDATA[ZymoGenetics Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=23449</guid>
		<description><![CDATA[ZymoGenetics Inc. (ZGEN) announced recently that it has restructured the agreements with Bayer Schering Pharma AG and Bayer HealthCare relating to its bleeding control product Recothrom. The revised agreement, effective from Jan 1, 2010, will see Bayer stop promoting Recothrom in the United States.  Zymogenetics will promote the drug outside the U.S apart from Canada, where Bayer will market and sell the product. Consequently, ZymoGenetics will continue to get royalties on Recothrom sales in that country. Under the restructured agreements, Zymogenetics will pay commissions to Bayer which will steadily decrease over the next 24 months and will not have to pay bonuses on U.S. sales, while Bayer will pay royalties on Recothrom sales in Canada but won&#8217;t have to make milestone payments to ZymoGenetics.  Even though Bayer is slated to ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/12/22/zgen-zymogenetics-amends-recothrom-deal/23449/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ZGEN) ZymoGenetics Inc Inks Licensing Deal with Novo Nordisk A/S</title>
		<link>http://www.stockbloghub.com/2009/12/08/zgen-zymogenetics-inc-inks-licensing-deal-with-novo-nordisk-as/22228</link>
		<comments>http://www.stockbloghub.com/2009/12/08/zgen-zymogenetics-inc-inks-licensing-deal-with-novo-nordisk-as/22228#comments</comments>
		<pubDate>Tue, 08 Dec 2009 18:55:14 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Novo Nordisk A-S]]></category>
		<category><![CDATA[NVO]]></category>
		<category><![CDATA[ZGEN]]></category>
		<category><![CDATA[ZymoGenetics Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=22228</guid>
		<description><![CDATA[ZymoGenetics Inc. (ZGEN) announced recently that it has signed a deal with Novo Nordisk A/S (NVO) whereby the latter gets global rights to an antibody drug developed by ZymoGenetics to block Interleukin-21 (IL-21), a protein that’s found in excess in patients with autoimmune and inflammatory diseases. Novo Nordisk in-licensed intellectual property rights to IL-21 antibodies outside North America in 2001 and now possesses global rights. The terms of the deal require Novo Nordisk to make an initial upfront cash payment of $24 million to ZymoGenetics. Furthermore, with the progress of the development program of the IL-21 monoclonal antibody, ZymoGenetics stands to receive milestones from Novo Nordisk up to $157.5 million over the period of the agreement. The amount includes a $1.5 million milestone payment to be made once an investigational ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/12/08/zgen-zymogenetics-inc-inks-licensing-deal-with-novo-nordisk-as/22228/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>($KG) King Pharmaceuticals Beats Consensus, but Earnings Down</title>
		<link>http://www.stockbloghub.com/2009/11/07/kg-king-pharmaceuticals-beats-consensus-but-earnings-down/19827</link>
		<comments>http://www.stockbloghub.com/2009/11/07/kg-king-pharmaceuticals-beats-consensus-but-earnings-down/19827#comments</comments>
		<pubDate>Sun, 08 Nov 2009 00:35:35 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[KG]]></category>
		<category><![CDATA[King Pharmaceuticals Inc.]]></category>
		<category><![CDATA[Pain Therapeutics Inc.]]></category>
		<category><![CDATA[PTIE]]></category>
		<category><![CDATA[ZGEN]]></category>
		<category><![CDATA[ZymoGenetics Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=19827</guid>
		<description><![CDATA[King Pharmaceuticals, Inc. (KG) reported third quarter earnings of 29 cents per share, beating the Zacks Consensus Estimate by 2 cents. Despite revenues increasing 19.3% from the year-ago period, earnings declined 25.6% from the year-ago quarter mainly due to higher operating expenses. Total revenues came in at $463.3 million. The primary growth drivers were the Animal Health business, which came as a part of the Alpharma acquisition and an increase in sales of auto-injectors in the Meridian business. King’s branded pharmaceuticals segment posted revenues of $283 million, down 6.3% from the prior-year period. While generic versions of Altace continued to impact the top-line, both Skelaxin and Thrombin-JMI sales continued to decline on a year-over-year basis. Thrombin-JMI sales came in at $43 million, down 35.8%. We expect Thrombin-JMI sales to continue ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/11/07/kg-king-pharmaceuticals-beats-consensus-but-earnings-down/19827/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

